(Q39979882)

English

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

0 references

decision making

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Y Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

C Sung

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

C Dartois

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

R Ramchandani

4

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

B P Booth

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

E Rock

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

J Gobburu

7

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

language of work or name

0 references

publication date

13 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

86

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

167-174

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Can the pharmaceutical industry reduce attrition rates?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Prognostic factors in non-small cell lung cancer: a decade of progress

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Diameter of non-small cell lung cancer correlates with long-term survival: implications for T stage.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Tumor Size Predicts Survival Within Stage IA Non-Small Cell Lung Cancer *

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Unexpected observations on tumor size and survival in stage IA non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Predicting the course of Gompertzian growth

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Imaging as a tumor biomarker in oncology drug trials for lung cancer: the FDA perspective

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

21 January 2018

Accelerated approval of oncology products: a decade of experience

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.64

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2009.64

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39979882&oldid=1881678987"